The prognostic value of combined preoperative PLR and CA19-9 in patients with resectable gallbladder cancer
Updates in Surgery - 2024
Tóm tắt
The platelet to lymphocyte ratio (PLR) is the marker of host inflammation and it is a potential significant prognostic indicator in various different tumors. The serum carbohydrate antigen 19–9 (CA19-9) is a tumor-associated antigen and it is associated with poor prognosis of gallbladder cancer (GBC). We aimed to analyze the prognostic value of the combination of preoperative PLR and CA19-9 in patients with GBC. A total of 287 GBC patients who underwent curative surgery in our institution was included. To analyze the relationship between PLR and CA19-9 and clinicopathological features. A receiver operating characteristic (ROC) curve was used to identify the optimal cutoff value for PLR and CA19-9. The Kaplan–Meier method was used to estimate the overall survival (OS). Meanwhile, the univariate and multivariate Cox regression models were used to assess the risk factors for OS. The cutoff values of 146.82 and 36.32U/ml defined as high PLR and high CA19-9, respectively. Furthermore, survival analysis showed that patients with PLR > 146.82 and CA19-9 > 36.32 U/ml had a worse prognosis than patients with PLR ≤ 146.82 and CA19-9 ≤ 36.32 U/ml, respectively. The multivariate analysis demonstrated that PLR (hazard ratio (HR) = 1.863, 95% CI: 1.366–2.542, P < 0.001) and CA19-9 (HR = 1.412, 95% CI: 1.021–1.952, P = 0.037) were independent prognostic factors in the GBC patients. When we combined these two parameters, the area under the ROC curve increased from 0.624 (PLR) and 0.661 (CA19-9) to 0.711. In addition, the 1-, 3-, and 5-year OS of group A (patients with PLR ≤ 146.82 and CA19-9 ≤ 36.32 U/ml), group B (patients with either of PLR > 146.82 or CA19-9 > 36.32 U/ml) and group C (patients with PLR > 146.82 and CA19-9 > 36.32 U/ml) were 83.6%, 58.6%, 22.5%, 52.4%, 19.5%, 11.5%, and 42.3%, 11.9%, 0%, respectively. The preoperative PLR and serum CA19-9 are associated with prognosis of patients with GBC. The combination of PLR and CA19-9 may serve as a significant prognostic biomarker for GBC patients superior to either PLR or CA19-9 alone.
Từ khóa
Tài liệu tham khảo
Roa JC, García P, Kapoor VK, Maithel SK, Javle M, Koshiol J (2022) Gallbladder cancer. Nat Rev Dis Primers 8(1):69
Song X, Hu Y, Li Y, Shao R, Liu F, Liu Y (2020) Overview of current targeted therapy in gallbladder cancer. Signal Transduct Target Ther 5(1):230
Gunasekaran G, Bekki Y, Lourdusamy V, Schwartz M (2021) Surgical treatments of hepatobiliary cancers. Hepatology 73(Suppl 1):128–136
Hickman L, Contreras C (2019) Gallbladder cancer: diagnosis, surgical management, and adjuvant therapies. Surg Clin North America 99(2):337–355
Ito H, Matros E, Brooks DC et al (2004) Treatment outcomes associated with surgery for gallbladder cancer: a 20-year experience. J Gastrointes Surg 8(2):183–190
Butte JM, Matsuo K, Gönen M et al (2011) Gallbladder cancer: differences in presentation, surgical treatment, and survival in patients treated at centers in three countries. J Am Coll Surg 212(1):50–61
Yifan T, Zheyong L, Miaoqin C, Liang S, Xiujun C (2018) A predictive model for survival of gallbladder adenocarcinoma. Surg Oncol 27(3):365–372
Hakeem AR, Papoulas M, Menon KV (2019) The role of neoadjuvant chemotherapy or chemoradiotherapy for advanced gallbladder cancer - A systematic review. Eur J Surg Oncol 45(2):83–91
Abdel-Rahman O, Elsayed Z, Elhalawani H (2018) Gemcitabine-based chemotherapy for advanced biliary tract carcinomas. Cochrane Database System Rev 4(4):Cd011746
Grivennikov SI, Greten FR, Karin M (2010) Immunity, inflammation, and cancer. Cell 140(6):883–899
Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144(5):646–674
Zhang L, Wang R, Chen W et al (2016) Prognostic significance of neutrophil to lymphocyte ratio in patients with gallbladder carcinoma. HPB (Oxford) 18(7):600–607
Stone RL, Nick AM, McNeish IA et al (2012) Paraneoplastic thrombocytosis in ovarian cancer. N Engl J Med 366(7):610–618
Templeton AJ, Ace O, McNamara MG et al (2014) Prognostic role of platelet to lymphocyte ratio in solid tumors: a systematic review and meta-analysis. Cancer Epidemiol Biomarkers Prev 23(7):1204–1212
Diem S, Schmid S, Krapf M et al (2017) Neutrophil-to-Lymphocyte ratio (NLR) and Platelet-to-Lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with nivolumab. Lung cancer (Amsterdam, Netherlands) 111:176–181
Xia WK, Liu ZL, Shen D, Lin QF, Su J, Mao WD (2016) Prognostic performance of pre-treatment NLR and PLR in patients suffering from osteosarcoma. World J Surg Oncol 14:127
Smith RA, Ghaneh P, Sutton R, Raraty M, Campbell F, Neoptolemos JP (2008) Prognosis of resected ampullary adenocarcinoma by preoperative serum CA19-9 levels and platelet-lymphocyte ratio. J Gastrointes Surg 12(8):1422–1428
Schobert IT, Savic LJ, Chapiro J et al (2020) Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios as predictors of tumor response in hepatocellular carcinoma after DEB-TACE. Eur Radiol 30(10):5663–5673
Feng F, Tian Y, Xu G et al (2017) Diagnostic and prognostic value of CEA, CA19-9, AFP and CA125 for early gastric cancer. BMC Cancer 17(1):737
Bind MK, Mishra RR, Kumar V, Misra V, Singh PA (2021) Serum CA 19–9 and CA 125 as a diagnostic marker in carcinoma of gallbladder. Indian J Pathol Microbiol 64(1):65–68
Luo G, Jin K, Cheng H et al (2017) Carbohydrate antigen 19–9 as a prognostic biomarker in pancreatic neuroendocrine tumors. Oncol Lett 14(6):6795–6800
!!! INVALID CITATION !!! {}.
Lee JO, Kim M, Lee JH et al (2023) Carbohydrate antigen 19–9 plus carcinoembryonic antigen for prognosis in colorectal cancer: An observational study. Colorectal Dis 25(2):272–281
Regimbeau JM, Fuks D, Bachellier P et al (2011) Prognostic value of jaundice in patients with gallbladder cancer by the AFC-GBC-2009 study group. Eur J Surg Oncol 37(6):505–512
Wang JW, Peng SY, Li JT et al (2009) Identification of metastasis-associated proteins involved in gallbladder carcinoma metastasis by proteomic analysis and functional exploration of chloride intracellular channel 1. Cancer Lett 281(1):71–81
Li D, Yang Z, Liu Z, Zou Q, Yuan Y (2020) Clinical Significance of CBS and CCL21 in Gallbladder Adenocarcinomas and Squamous Cell/Adenosquamous Carcinomas. Appl Immunohistochem Mol Morphol 28(2):103–110
Bambace NM, Holmes CE (2011) The platelet contribution to cancer progression. J Thrombosis Haemostasis 9(2):237–249
Wang RT, Zhang LQ, Mu YP et al (2015) Prognostic significance of preoperative platelet count in patients with gallbladder cancer. World J Gastroenterol 21(17):5303–5310
Dunn GP, Old LJ, Schreiber RD (2004) The immunobiology of cancer immunosurveillance and immunoediting. Immunity 21(2):137–148
Conci S, Campagnaro T, Danese E et al (2021) Role of inflammatory and immune-nutritional prognostic markers in patients undergoing surgical resection for biliary tract cancers. Cancers 13(14):3594
Zhang Y, Jiang C, Li J, Sun J, Qu X (2015) Prognostic significance of preoperative neutrophil/lymphocyte ratio and platelet/lymphocyte ratio in patients with gallbladder carcinoma. Clin Trans Oncol 17(10):810–818
Koprowski H, Steplewski Z, Mitchell K, Herlyn M, Herlyn D, Fuhrer P (1979) Colorectal carcinoma antigens detected by hybridoma antibodies. Somatic Cell Genet 5(6):957–971
Hong EK, Kim KK, Lee JN et al (2014) Surgical outcome and prognostic factors in patients with gallbladder carcinoma. Korean J Hepato-Biliary-Pancreat Surg 18(4):129–137
Liu F, Hu HJ, Ma WJ, Yang Q, Wang JK, Li FY (2019) Prognostic significance of neutrophil-lymphocyte ratio and carbohydrate antigen 19–9 in patients with gallbladder carcinoma. Medicine 98(8):e14550
Bartlett DL, Fong Y, Fortner JG, Brennan MF, Blumgart LH (1996) Long-term results after resection for gallbladder cancer. Implications for staging and management. Annals Surg 224(5):639–646